PL3684344T3 - Tabletki deferypronu o opóźnionym uwalnianiu i sposoby ich zastosowania - Google Patents
Tabletki deferypronu o opóźnionym uwalnianiu i sposoby ich zastosowaniaInfo
- Publication number
- PL3684344T3 PL3684344T3 PL18871663.3T PL18871663T PL3684344T3 PL 3684344 T3 PL3684344 T3 PL 3684344T3 PL 18871663 T PL18871663 T PL 18871663T PL 3684344 T3 PL3684344 T3 PL 3684344T3
- Authority
- PL
- Poland
- Prior art keywords
- deferypron
- delayed
- methods
- release tablets
- tablets
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577055P | 2017-10-25 | 2017-10-25 | |
| US201762596043P | 2017-12-07 | 2017-12-07 | |
| PCT/IB2018/058350 WO2019082128A1 (en) | 2017-10-25 | 2018-10-25 | DELAYED-RELEASE RELEASE TABLETS AND METHODS OF USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3684344T3 true PL3684344T3 (pl) | 2025-10-27 |
Family
ID=66170815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18871663.3T PL3684344T3 (pl) | 2017-10-25 | 2018-10-25 | Tabletki deferypronu o opóźnionym uwalnianiu i sposoby ich zastosowania |
Country Status (29)
| Country | Link |
|---|---|
| US (8) | US20200253945A1 (pl) |
| EP (2) | EP3684344B1 (pl) |
| JP (1) | JP7246384B2 (pl) |
| KR (1) | KR102624627B1 (pl) |
| CN (2) | CN111918646B (pl) |
| AU (1) | AU2018357350B2 (pl) |
| BR (1) | BR112020008128A2 (pl) |
| CA (2) | CA3077514C (pl) |
| DK (1) | DK3684344T3 (pl) |
| ES (1) | ES3036967T3 (pl) |
| FI (1) | FI3684344T3 (pl) |
| HR (1) | HRP20251151T1 (pl) |
| IL (2) | IL321388A (pl) |
| LT (1) | LT3684344T (pl) |
| MA (1) | MA50201B1 (pl) |
| MD (1) | MD3684344T2 (pl) |
| MX (1) | MX2020004107A (pl) |
| MY (1) | MY204588A (pl) |
| NZ (2) | NZ763555A (pl) |
| PH (1) | PH12020550815A1 (pl) |
| PL (1) | PL3684344T3 (pl) |
| PT (1) | PT3684344T (pl) |
| RS (1) | RS67157B1 (pl) |
| SA (1) | SA520411808B1 (pl) |
| SG (1) | SG11202003153TA (pl) |
| SI (1) | SI3684344T1 (pl) |
| SM (1) | SMT202500358T1 (pl) |
| UA (1) | UA126977C2 (pl) |
| WO (1) | WO2019082128A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3077514C (en) | 2017-10-25 | 2022-10-11 | Chiesi Farmaceutici S.P.A. | Delayed release deferiprone tablets and methods of using the same |
| US12016850B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| US12016851B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| WO2023198640A1 (en) | 2022-04-11 | 2023-10-19 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| CN119300809A (zh) | 2022-04-11 | 2025-01-10 | 奇斯药制品公司 | 包含去铁酮的调节释放药物制剂 |
| CN120076797A (zh) * | 2022-10-14 | 2025-05-30 | 奇斯药制品公司 | 包含去铁酮的调释药物制剂 |
| WO2024240775A1 (en) | 2023-05-25 | 2024-11-28 | Chiesi Farmaceutici S.P.A. | Pharmaceutical dosage forms for pulsatile release |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI98343C (fi) * | 1995-03-21 | 1997-06-10 | Orion Yhtymae Oy | Peroraalinen formulaatio |
| US5747532A (en) | 1995-11-21 | 1998-05-05 | Medinox, Inc. | Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor |
| GB9625638D0 (en) | 1996-12-10 | 1997-01-29 | Cenes Ltd | Therapeutic antioxidants for alzheimer's diease |
| WO2001049266A2 (en) | 1999-12-30 | 2001-07-12 | Gwathemy Judith K | Iron chelator delivery system |
| CA2313270C (en) * | 2000-06-30 | 2011-09-13 | Apotex Inc. | Use of deferiprone in treating and preventing iron-induced cardiac disease |
| AU2003251920A1 (en) | 2002-07-12 | 2004-02-02 | The Buck Institute For Research On Aging | Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
| AU2003282337B2 (en) | 2002-11-07 | 2009-07-16 | Technion Research And Development Foundation Ltd. | Neuroprotective iron chelators and pharmaceutical compositions comprising them |
| JP2008509149A (ja) * | 2004-08-06 | 2008-03-27 | シバ バイオメディカル，エルエルシー | 造影剤の注入を受けるヒトの処置方法 |
| GB0502475D0 (en) * | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
| AU2007219009B2 (en) | 2006-02-22 | 2012-12-20 | Apotex Technologies Inc. | The use of deferiprone and methods to treat and/or prevent Friedreich Ataxia resulting from intracellular mishandling of iron |
| EP2063871A1 (en) * | 2006-08-30 | 2009-06-03 | Jagotec AG | Controlled release solid oral dosage formulations comprising nisoldipine |
| US9744137B2 (en) * | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| US20080138440A1 (en) * | 2006-11-29 | 2008-06-12 | Cormedix Inc. | Methods of diagnosing and alleviating gadolinium toxicity |
| CN101352438A (zh) | 2007-07-25 | 2009-01-28 | 复旦大学 | 去铁酮及其制剂在制备防治蒽环类药物心脏毒性药物中的用途 |
| EA022751B1 (ru) | 2008-04-25 | 2016-02-29 | Апотекс Текнолоджиз Инк. | Жидкая композиция деферипрона с замаскированным вкусом |
| US20110189260A1 (en) | 2008-05-30 | 2011-08-04 | University Of Cincinnati | Use of zinc chelators to inhibit biofilm formation |
| WO2010005851A1 (en) | 2008-07-08 | 2010-01-14 | Xenon Pharmaceuticals Inc. | Combination therapy for treating iron disorders |
| US20100255082A1 (en) * | 2008-07-31 | 2010-10-07 | Ishwar Chauhan | Functionally Coated Breakable Tablets |
| EP2206506A1 (en) | 2008-12-18 | 2010-07-14 | Bracco Imaging S.p.A | Probiotic formulations |
| AP2011005843A0 (en) | 2009-01-26 | 2011-08-31 | Joshua Lawrence Dunaief | Use of deferiprone for treatment and prevention ofiron-related eye disorders. |
| US8603814B2 (en) | 2009-07-20 | 2013-12-10 | Rutgers The State University Of New Jersey | Method of inhibiting nonsense-mediated mRNA decay |
| US20120172292A1 (en) | 2009-09-10 | 2012-07-05 | New York University | Method for protection of antimicrobial and anticancer drugs from inactivation by nitric oxide |
| US8563035B2 (en) * | 2010-05-05 | 2013-10-22 | Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi | Oral tablet compositions of dexlansoprazole |
| JP2014501784A (ja) * | 2011-01-07 | 2014-01-23 | メリオン・リサーチ・Ｉｉｉ・リミテッド | 経口投与用の鉄の医薬組成物 |
| DE102011112898A1 (de) * | 2011-09-08 | 2013-03-14 | Charité - Universitätsmedizin Berlin | Nanopartikuläres Phosphatadsorbens basierend auf Maghämit oder Maghämit/Magnetit, dessen Herstellung und Verwendungen |
| EP2780012A4 (en) | 2011-11-18 | 2015-07-29 | Apotex Technologies Inc | Methods of treatment with deferiprone |
| WO2013139931A1 (en) | 2012-03-21 | 2013-09-26 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Composition for use in the treatment of neurodegenerative diseases with parkinsonian syndromes |
| MX2015003729A (es) * | 2012-11-12 | 2015-06-15 | Cipla Ltd | Composiciones farmaceuticas de dosis fija que comprende deferasirox y deferiprona. |
| AU2014264421A1 (en) * | 2013-05-10 | 2015-12-03 | Cipla Limited | Low dose pharmaceutical composition |
| EP3003328B1 (en) | 2013-06-06 | 2021-07-28 | Albion Laboratories, Inc. | Iron supplement |
| ITMI20132066A1 (it) | 2013-12-11 | 2015-06-12 | Farmatron Ltd | Sistemi terapeutici a rilascio modificato per la somministrazione orale di mentolo nel trattamento delle malattie intestinali |
| JP7125396B2 (ja) | 2016-08-05 | 2022-08-24 | アブフェロ ファーマシューティカルズ，インコーポレイテッド | 金属誘発性疾患を治療するための投与レジメン |
| US20180362228A1 (en) | 2017-02-16 | 2018-12-20 | Jeffrey D. Jacobson | Container closure with integrated utensil |
| CA3077514C (en) | 2017-10-25 | 2022-10-11 | Chiesi Farmaceutici S.P.A. | Delayed release deferiprone tablets and methods of using the same |
-
2018
- 2018-10-25 CA CA3077514A patent/CA3077514C/en not_active Expired - Fee Related
- 2018-10-25 SG SG11202003153TA patent/SG11202003153TA/en unknown
- 2018-10-25 MA MA50201A patent/MA50201B1/fr unknown
- 2018-10-25 CN CN201880069331.7A patent/CN111918646B/zh active Active
- 2018-10-25 EP EP18871663.3A patent/EP3684344B1/en active Active
- 2018-10-25 MX MX2020004107A patent/MX2020004107A/es unknown
- 2018-10-25 JP JP2020523267A patent/JP7246384B2/ja active Active
- 2018-10-25 RS RS20250792A patent/RS67157B1/sr unknown
- 2018-10-25 DK DK18871663.3T patent/DK3684344T3/da active
- 2018-10-25 BR BR112020008128-0A patent/BR112020008128A2/pt unknown
- 2018-10-25 HR HRP20251151TT patent/HRP20251151T1/hr unknown
- 2018-10-25 CA CA3172668A patent/CA3172668A1/en not_active Withdrawn
- 2018-10-25 US US16/759,254 patent/US20200253945A1/en not_active Abandoned
- 2018-10-25 FI FIEP18871663.3T patent/FI3684344T3/fi active
- 2018-10-25 SI SI201831250T patent/SI3684344T1/sl unknown
- 2018-10-25 LT LTEPPCT/IB2018/058350T patent/LT3684344T/lt unknown
- 2018-10-25 KR KR1020207014502A patent/KR102624627B1/ko active Active
- 2018-10-25 US US16/171,173 patent/US10780055B2/en active Active
- 2018-10-25 PT PT188716633T patent/PT3684344T/pt unknown
- 2018-10-25 WO PCT/IB2018/058350 patent/WO2019082128A1/en not_active Ceased
- 2018-10-25 EP EP25186255.3A patent/EP4635573A2/en active Pending
- 2018-10-25 SM SM20250358T patent/SMT202500358T1/it unknown
- 2018-10-25 AU AU2018357350A patent/AU2018357350B2/en active Active
- 2018-10-25 NZ NZ763555A patent/NZ763555A/en unknown
- 2018-10-25 MD MDE20200792T patent/MD3684344T2/ro unknown
- 2018-10-25 PL PL18871663.3T patent/PL3684344T3/pl unknown
- 2018-10-25 UA UAA202003078A patent/UA126977C2/uk unknown
- 2018-10-25 NZ NZ787785A patent/NZ787785A/en unknown
- 2018-10-25 MY MYPI2020002003A patent/MY204588A/en unknown
- 2018-10-25 US US16/171,170 patent/US10940116B2/en active Active
- 2018-10-25 CN CN202210164525.3A patent/CN114533689A/zh active Pending
- 2018-10-25 IL IL321388A patent/IL321388A/en unknown
- 2018-10-25 ES ES18871663T patent/ES3036967T3/es active Active
-
2019
- 2019-12-13 US US16/714,520 patent/US11458103B2/en active Active
-
2020
- 2020-04-03 US US16/839,928 patent/US11357731B2/en active Active
- 2020-04-13 IL IL273955A patent/IL273955B2/en unknown
- 2020-04-20 PH PH12020550815A patent/PH12020550815A1/en unknown
- 2020-04-21 SA SA520411808A patent/SA520411808B1/ar unknown
- 2020-05-12 US US15/930,373 patent/US10940115B2/en active Active
-
2021
- 2021-05-21 US US17/327,135 patent/US11723874B2/en active Active
-
2022
- 2022-05-12 US US17/742,960 patent/US11607389B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271025A (en) | Multibiotic agents and methods of using the same | |
| DK3774789T3 (da) | BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse | |
| DK3601358T3 (da) | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3618863T3 (da) | Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| PL3558339T3 (pl) | Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania | |
| DK3353210T3 (da) | Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse | |
| DK3436048T3 (da) | Neoantigener og fremgangsmåder til anvendelse deraf | |
| DK3259597T3 (da) | Pvrig-polypeptider og fremgangsmåder til behandling | |
| DK3356404T3 (da) | Anti-pd1-antistoffer og fremgangsmåder til anvendelse | |
| DK3653221T3 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| PL3684344T3 (pl) | Tabletki deferypronu o opóźnionym uwalnianiu i sposoby ich zastosowania | |
| PL3250610T3 (pl) | Przeciwciała anty-FcRn i sposoby ich stosowania | |
| DK3209681T3 (da) | Farmaceutiske sammensætninger omfattende peptidvarianter og fremgangsmåder til anvendelse deraf | |
| DK3310812T3 (da) | Anti-HER2-antistoffer og fremgangsmåder til anvendelse | |
| DK3828194T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| PL3265448T3 (pl) | Proleki riluzolu i ich zastosowanie | |
| DK3426781T3 (da) | Mikro-rna'er og fremgangsmåder til anvendelse deraf | |
| DK3514151T3 (da) | Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf | |
| DK3710430T3 (da) | Acss2-inhibitorer og fremgangsmåder til anvendelse deraf | |
| DK3525583T3 (da) | Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf | |
| IL254670A0 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
| DK3089971T3 (da) | Forbindelser og fremgangsmåder til anvendelse | |
| DK3812392T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf |